BOSTON, Mass., February 13, 2012 – OvaScience™, an innovative life science company dedicated to improving the treatment of infertility, today announced that the company will present at the Leerink Swann 2012 Global Healthcare Conference, being held February 15-16 at The Waldorf Astoria Hotel in New York City. Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present an overview of the company on Wednesday, February 15th at 10:45 a.m.
About OvaScience™ OvaScience is an innovative life science company dedicated to improving the treatment of infertility. OvaScience's first product, AUGMENT, aims to increase the success of in vitro fertilization (IVF). OvaScience's patented technology, exclusively licensed from Harvard Medical School and Massachusetts General Hospital, allows a woman to use her own cellular energy to revitalize her egg. The company's team of scientists, physicians and advisers are recognized leaders in the field of reproductive medicine. Privately-held OvaScience was co-founded by Rich Aldrich, Michelle Dipp, M.D., Ph.D., and Christoph Westphal, M.D., Ph.D., of Longwood Fund, and Professors Jonathan Tilly, Ph.D., of Massachusetts General Hospital and Harvard Medical School, and David Sinclair, Ph.D., of Harvard Medical School. For more information, please visit the company’s website at www.ovascience.com.